Hikma wins Company of the Year at the Global Generics & Biosimilars Awards 2017

London, 3 November 2017 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable) is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for the global generics industry, has awarded the company with the Company of the Year Award at the Global Generics & Biosimilars Awards 2017.

Press Release Corporate 3 November 2017

Content

“We are extremely proud to have received this recognition of the role we are play in providing quality, affordable medicines to improve health around the world.  For nearly 40 years this has been our driving purpose, and it still motivates us everyday,” said Said Darwazah, Chairman and CEO of Hikma.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.